Monday March 26, 8:00 am Eastern Time
Press Release
EchoCath's Portable Blood Velocity Measurement System
Receives FDA 510K Clearance-To-Market
PRINCETON, N.J.--(BUSINESS WIRE)--March 26, 2001--EchoCath, Inc. (NASD-OTC:ECHTA)
announced today it has been granted permission by the U.S. Food and Drug Administration to market
its EchoFlow(TM) battery powered, portable blood velocity measurement system (EchoFlow PEF-1).
EchoFlow PEF-1 is a battery powered and portable angle-independent blood velocity measuring system
that enables physicians to evaluate and quantify blood flow in vessels using ultrasound technology.
Blood velocity is an important parameter of circulatory system health. In addition to EchoCath's
EchoFlow(TM) BVM-1 system designed for use in the operating room for blood velocity measurement,
the EchoFlow(TM) PEF-1 extends the usefulness of EchoCath's proprietary ultrasound technology.
Intensive care units, dialysis facilities and clinics are areas of hospitals where physicians have had the
need for accurate blood velocity measurement but have not had cost effective readily available
equipment. The EchoFlow(TM) PEF-1 system addresses these needs.
EchoCath President, Frank DeBernardis commented, ``We are pleased that surgeons who have been
using our EchoFlow(TM) BVM-1 in clinical evaluations have been impressed with the systems and
have identified a number of applications for the technology outside of the operating room. The
EchoFlow(TM) PEF-1 is EchoCath's response to their input.'' The Company will be exhibiting this
technology at the Society for Clinical Vascular Surgery 29th Annual Symposium in Boca Raton, Florida
on April 5-7th.
Certain statements herein constitute ``forward-looking statements'' within the meaning of the Private
Securities Litigation Reform Act of 1995, including without limitation statements regarding acceptability
by vascular surgeons and physicians of the Company's technology. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors which may cause the actual results,
performance or achievements of the Company to be materially different from any future results,
performance or achievements expressed or implied by such forward-looking statements. Such factors
include, among others, the following: limited commercial operations; no assurances of success; need for
additional financing; uncertainty of market acceptance; failure to receive or delays in receiving
regulatory approval; lack of a distribution channel for the Company's products; and limitations on third
party reimbursement. Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof.
Contact:
EchoCath, Inc.
Frank DeBernardis, 609/987-8400 |
